Here's Why Neurocrine Biosciences Is Soaring

Here's Why Neurocrine Biosciences Is Soaring

In response to the company reporting better-than-expected quarterly results, shares of Neurocrine Biosciences (NASDAQ: NBIX), a commercial stage biotech focused on neurological and endocrine disorders, rose 17% as of 11:45 a.m. EDT Thursday.

Here's a review of the key takeaways from the company's third quarter:

Commenting on the quarter, CEO Kevin Gorman stated:

Continue reading

Source: Fool.com